Cytotoxicity-inducing therapeutic agent
US11001643B2 · kind B2 · utility
4Cited by
73References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2018 |
| Grant date | May 11, 2021 |
| Priority date | — |
| Expiry date | Feb 17, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Multi specific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity are provided. Since the provided molecules show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce pharmaceutical compositions for treating or preventing various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.